Circulating human mononuclear cells exhibit augmented lysis of pig endothelium after activation with interleukin 2

Transplantation

Volumn 62, Issue 12, 1996, Pages 1927-1933

  Itescu, S ^a,b   Kwiatkowski, P ^a   Wang, S F ^a   Blood, T ^a   Minanov, O P ^a   Rose, S ^a   Michler, R E ^a  

^a New York State Psychiat Inst and New York Presbyterian Hospital Columbia University Medical Center   (United States)

^b Milstein Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

ANIMAL EXPERIMENT; BABOON; CONFERENCE PAPER; GRAFT REJECTION; GUINEA PIG; HUMAN; HUMAN CELL; MONONUCLEAR CELL; NATURAL KILLER CELL; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM; XENOGRAFT;

ANIMALS; ANTIBODIES; ANTIGENS, CD2; AORTA; CELL ADHESION; CELL DEATH; CYTOTOXICITY, IMMUNOLOGIC; ENDOTHELIUM, VASCULAR; GRAFT REJECTION; GUINEA PIGS; HEART TRANSPLANTATION; HUMANS; INTERLEUKIN-1; INTERLEUKIN-2; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; TRANSPLANTATION, HETEROLOGOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030473294     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199612270-00043     Document Type: Conference Paper

References (45)

1. Sandrin MS, Vaughan HA, Dabkowski PL, Mckenzie IFC. Anti-pig IgM antibodies in human serum react predominantly with Gal (alpha 1-3) Gal epitopes. Proc Natl Acad Sci 1993; 90: 11391.
2. Cooper DKC, Good AH, Koren E, et al. Identification of alpha-galactosyl residues and other carbohydrate epitopes that are bound by human anti-pig antibodies: relevance to discordant xenografting in man. Transplant Immunol 1993; 1: 198.
3. Rosengard AM, Cary N, Horsley J, et al. Endothelial expression of human decay accelerating factor in transgenic pig tissue: a potential approach for human complement inactivation in discordant xenografts. Transplant Proc 1995; 27(1): 326.
4. Thorley BR, McInnes B, Christiansen D, McKenzie IFC, Loveland BE. Construction of CD46 minigenes for the production of transgenic mice. Transplant Proc 1995; 27: 2177.
5. Xu H, Edwards NM, Chen JM, Kwiatkowski P, Rosenberg SE, Michler RE. Newborn baboon serum lacks natural anti-pig xenoantibody. Transplantation 1995; 59(8): 1189.
6. Kaplon RJ, Michler RE, Xu H, Kwiatkowski PA, Edwards N, Platt J. Absence of hyperacute rejection in newborn pig-to-baboon cardiac xenografts. Transplantation 1995; 59: 1.
7. Michler RE, Xu H, O'Hair DP, et al. Newborn discordant cardiac xenotransplantation in primates: a model of natural antibody depletion. Transplant Proc 1996; 28: 661.
8. Itescu S, Minanov O, Kwiatkowski P, Platt J, Michler RE. Delayed rejection of newborn pig-to-baboon cardiac xenografts involves both cellular and humoral immune mechanisms. [Abstract]. Proceedings of the International Society for Heart Lung Transplantation. St. Louis: Mosby-Year Book, 1996.
9. Hancock WW, Blakely ML, Van der Werf W, Bach FH. Rejection of guinea pig cardiac xenografts post-cobra venom factor therapy is associated with infiltration by mononuclear cells secreting interferon-gamma and diffuse endothelial activation. Transplant Proc 1993; 25: 2932.
10. Blakely ML, Van der Werf WJ, Berndt MC, Dalmasso AP, Bach FH, Hancock WW. Activation of intragraft endothelial and mononuclear cells during discordant xenograft rejection. Transplantation 1994; 58(10): 105.
11. Inverardi L, Samaja M, Motterlini R, Mangili F, Bender JR, Pardi R. Early recognition of a discordant xenogeneic organ by human circulating lymphocytes. J Immunol 1992; 149: 1416.
12. Inverardi L, Pardi R. Early events in cell-mediated recognition of vascularized xenografts: cooperative interactions between selected lymphocyte subsets and natural antibodies. Immunol Rev 1994; 141: 71.
13. Minanov OP, Itescu S, Neethling FA, et al. Anti-Gal IgG antibodies in sera of newborn humans and baboons and its significance in pig xenotransplantation. Transplantation (in press).
14. Malyguine AM, Saadi S, Platt JL, Dawson JR. Human natural killer cells induce morphologic changes in porcine endothelial cell monolayers. Transplantation 1996; 61(1): 161.
15. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155(6): 1823.
16. Roberts K, Lotze MT, Rosenberg SA. Separation and functional studies of the human lymphokine-activated killer cell. Cancer Res 1987; 47(16): 4366.
17. Damle NK, Doyle LV, Bender JR, Bradley EC. Interleukin 2-activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis. J Immunol 1987; 138(6): 1779.
18. Kotasek D, Vercellotti GM, Ochoa AC, Bach FH, White JG, Jacob HS. Mechanism of cultured endothelial injury induced by lymphokine activated killer cells. Cancer Res 1988; 48(19): 5528.
19. Mier JW, Brandon EP, Libby P, Janicka MW, Aronson FR. Activated endothelial cells resist lymphokine-activated killer cell-mediated injury. Possible role of induced cytokines in limiting capillary leak during IL-2 therapy. J Immunol 1989; 143(7): 2407.
20. Salvo G, Samoggia P, Masciulli R, et al. Interleukin-2 bolus therapy induces immediate and selective disappearance from peripheral blood of all lymphocyte subpopulations displaying natural killer activity: role of cell adhesion to endothelium. Eur J Cancer 1992; 28A(4-5): 818.
21. Kitayama J, Tsuno N, Yasuhara H, et al. Lysis of endothelial cells by autologous lymphokine-activated killer cells. Immunotherapy 1994; 38(5): 317.
22. Kaplon RJ, Platt JL, Kwiatkowski PA, et al. Absence of hyper-acute rejection in pig-to-primate orthotopic pulmonary xenografts. Transplantation 1995; 59(3): 410.
23. Voyta JC, David PV, Butterfield CE, Zetter BR. Identification and isolation of endothelial cells based on their increased uptake of acetylated-low density lipoprotein. J Cell Biol 1985; 99: 2034.
24. Bravery CA, Rose ML, Yacoub MH. Proliferative responses of highly purified human CD4+ T cells to porcine endothelial cells. Transplant Proc 1994; 26: 1157.
25. Murray AG, Khodadoust MM, Pober JS, Bothwell AL. Porcine aortic endothelial cells activate human T cells: direct presentation of MHC antigens and costimulation by ligands for human CD2 and CD28. Immunity 1994; 1: 57.
26. Siliciano RF, Pratt JC, Schmidt RE, Ritz J, Reinherz EL. Activation of cytolytic T lymphocyte and natural killer cell function through the T11 sheep erythrocyte binding protein. Nature 1985; 317(6036): 428.
27. Anasetti C, Martin PJ, Morishita Y, Badger CC, Bernstein ID, Hansen JA. Human large granular lymphocytes express high affinity receptors for murine monoclonal antibodies of the IgG3 subclass. J Immunol 1987; 138(9): 2979.
28. Bolhuis RL, Roozemond RC, van de Griend RJ. Induction and blocking of cytolysis in CD2+, CD3- NK and CD2+, CD3+ cytotoxic T lymphocytes via CD2 50 KD sheep erythrocyte receptor. J Immunol 1986; 136(11): 3939.
29. Dustin ML, Sanders ME, Shaw S, Springer TA. Purified lymphocyte function-associated antigen 3 binds to CD2 and mediates T lymphocyte adhesion. J Exp Med 1987; 165(3): 677.
30. Arulanandam AR, Moingeon P, Concino MF, et al. A soluble multimeric recombinant CD2 protein identifies CD48 as a low affinity ligand for human CD2: divergence of CD2 ligands during the evolution of humans and mice. J Exp Med 1993; 177(5): 1439.
31. Sandrin MS, Mouhtouris E, Vaughan HA, Warren HS, Parish CR. CD48 is a low affinity ligand for human CD2. J Immunol 1993; 151(9): 4606.
32. Staunton DE, Fisher RC, LeBeau MM, et al. Blast-1 possesses a glycosylphosphatidylinositol (GPI) membrane anchor, is related to LFA-3 and OX-45, and maps to chromosome 1q21-23. J Exp Med 1989; 169(3): 1087.
33. Wallner BP, Frey AZ, Tizard R, et al. Primary structure of lymphocyte function-associated antigen 3 (LFA-3). The ligand of the T lymphocyte CD2 glycoprotein. J Exp Med 1987; 166(4): 923.
34. Seed B. An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2. Nature 1987; 329(6142): 840.
35. Qin L, Chavin KD, Lin J, Yagita H, Bromberg JS. Anti-CD2 receptor and anti-CD2 ligand (CD48) antibodies synergize to prolong allograft survival. J Exp Med 1994; 179(1): 341.
36. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76(2): 301.
37. Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol 1993; 11: 767.
38. Dustin ML, Springer TA. Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cell. J Cell Biol 1986; 107(1): 321.
39. Pober JS, Lapierre LA, Stolpen AH, et al. Activation of cultured human endothelial cells by recombinant lymphotoxin: comparison with tumor necrosis factor and interleukin 1 species. J Immunol 1987; 138(10): 3319.
40. Osborn L, Hession C, Tizard R, et al. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 1989; 59(6): 1203.
41. Swerlick RA, Garcia-Gonzalez E, Kubota Y, Xu YL, Lawley TJ. Studies of the modulation of MHC antigen and cell adhesion molecule expression on human dermal microvascular endothelial cells. J Invest Dermatol 1991; 97(2): 190.
42. Galea P, Lebranchu Y, Thibault G, Bardos P. Interleukin 4 and tumour necrosis factor alpha induce different adhesion pathways in endothelial cells for the binding of peripheral blood lymphocytes. Scand J Immunol 1992; 36(4): 575.
43. Kaji M, Ishikura H, Kishimoto T, et al. E-selectin expression induced by pancreas-carcinoma-derived interleukin 1 alpha results in enhanced adhesion of pancreas-carcinoma cells to endothelial cells. Int J Cancer 1995; 60(5): 712.
44. Allavena P, Paganin C, Martin-Padura I, et al. Molecules and structures involved in the adhesion of natural killer cells to vascular endothelium. J Exp Med 1991; 173: 439.
45. Ikuta S, Kirby JA, Shenton BK, et al. Human endothelial cells: effect of TNF-α on peripheral blood mononuclear cell adhesion. Immunology 1991; 73: 71.